Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response

Br J Haematol. 2019 May;185(4):770-772. doi: 10.1111/bjh.15611. Epub 2018 Oct 18.

Authors

Simone Bonecker¹, Gabriela Carvalho², Jane Dobbin³, Ilana Zalcberg¹, Rony Schaffel²

Affiliations

¹ Laboratory of Molecular Biology, Bone Marrow Transplant Centre (CEMO), Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
² University Hospital, Rio de Janeiro, Federal University (UFRJ), Rio de Janeiro, Brazil.
³ Haematology Service, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.

PMID: 30338507
DOI: 10.1111/bjh.15611

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use*
Dasatinib / therapeutic use
Drug Substitution
Female
Fusion Proteins, bcr-abl / metabolism
Humans
Imatinib Mesylate / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Middle Aged
Pyrimidines / therapeutic use
Survival Analysis
Young Adult

Substances

Antineoplastic Agents
Pyrimidines
Imatinib Mesylate
Fusion Proteins, bcr-abl
nilotinib
Dasatinib